Planning Manufacturing Systems That Grow With Your Cell And Gene Therapies

By Marisa Reinoso, Sr. Product Marketing Manager, Cell Therapy, Invetech

Cell and gene therapies (CGT) have the potential to reduce total disease costs by 18-30%, amounting to an aggregate cost savings of more than $33B over 10 years.¹ If the industry was able to reduce the costs of manufacturing, these savings would increase significantly.

CGT manufacturing requirements evolve from pre-clinical to clinical and commercial development, often significantly escalating costs at each step. There’s universal agreement in the industry that closing, integrating and automating manufacturing operations can drive significant cost reductions. Consequently, for most CGT manufacturers the question is not whether to close and automate, but rather when and how. What does an optimal manufacturing roadmap look like? How do you balance manufacturing flexibility with robustness and cost-effectiveness?